VENUS REMEDIES LTD. - 526953 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance under regulation 74(5) of SEBI DP regulations for the quarter ended on 30th June 2023.13-07-2023
13-07-2023
VENUS REMEDIES LTD. - 526953 - Update On Trading Restriction Of Venus Remedies Shares.
Update on trading restriction of Venus Remedies Shares.12-07-2023
VENUS REMEDIES LTD. - 526953 - Board Meeting Intimation for Notice Of Board Meeting To Be Held On 14Th July 2023.
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/07/2023 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 14th July 2023 inter alia: 1. To consider the appointment of Statutory Auditor of the Company. 2. To finalize the date of 34th Annual General Meeting of the company. 3. Any other business with permission of the Chair.05-07-2023
Venus Remedies jumps 3% on nod to operate in 4 foreign markets
The company has secured 503 marketing approvals for its oncology products across 75 countries.05-07-2023
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies oncology wing on expansion spree with marketing approvals from four key markets05-07-2023
VENUS REMEDIES LTD. - 526953 - Closure of Trading Window
Intimation of Closure of window.30-06-2023
Venus Remedies shares locked at 5% upper circuit as German arm gets Spanish regulator nod to market Meropenem in Spain
Venus Remedies' German subsidiary Venus Pharma GmbH has received this approval for 500mg, 1g and 2g injections of this last-recourse antibiotic.22-06-2023
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
VENUS REMEDIES BAGS APPROVAL TO MARKET MEROPENEM, ITS BLOCKBUSTER GENERIC DRUG, IN SPAIN.22-06-2023
Venus Remedies share price gains on GMP Certification from Ukraine
The share touched a 52-week high of Rs 263.55 and a 52-week low of Rs 145 on May 31, 2023 and February 8, 2023, respectively.07-06-2023
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.07-06-2023